China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions” of renminbi in a recent financing round. The round was led by YF Capital and Gree Group, with contributions from Z & H Investment and Shanzhi Investment. Proceeds will be used to advance the commercialization of gene editing diagnostic products and IND filings for novel drugs, establish a GMP-compliant drug R & D laboratory, ramp up technology innovation capabilities, and expand new drug pipelines.
Company Focus and Achievements
GeneRulor Medical Technology, focused on CRISPR molecular diagnosis and gene editing therapy, offers multiple detection kits covering early tumor screening, tumor companion diagnosis, genetic disease diagnosis, and pathogen detection. Notably, the company has concluded an investigator-initiated trial (ITT) for its HPV drug, showing good efficacy and safety results. An investigational new drug (IND) filing is being prepared.
Funding Round Details
The funding round led by YF Capital and Gree Group highlights the potential of GeneRulor Medical Technology in the gene editing field. The investment will support the company’s efforts in R & D, product commercialization, and pipeline expansion, aiming to bring more innovative gene editing diagnostic products and therapies to the market.-Fineline Info & Tech
